Pushkal  Garg net worth and biography

Pushkal Garg Biography and Net Worth

Dr. Pushkal Garg joined Alnylam in 2014 with 15 years of experience in clinical drug development. He oversees all clinical development activities at Alnylam.

Prior to joining Alnylam, Dr. Garg served as Vice President, Global Clinical Research, Immunoscience at Bristol-Myers Squibb (BMS). He was the strategic leader of the Immunoscience franchise and oversaw the development of multiple clinical assets across the areas of rheumatology, gastroenterology, nephrology, and transplantation. While at BMS, he was instrumental to the late-stage development and approval of Nulojix® (belatacept) for kidney transplant recipients, and for supplementary biologics license applications (BLAs) for Orencia® (abatacept). Preceding this, Dr. Garg held various roles at Millennium Pharmaceuticals, overseeing the clinical development of multiple small molecule and biologic therapeutics for the treatment of inflammatory disorders.

Dr. Garg received a Bachelor of Arts with high honors in Biochemistry from the University of California, Berkeley, and his M.D. from the University of California, San Francisco. He completed residency training in Internal Medicine at UCSF, was a fellow in the Robert Wood Johnson Clinical Scholars Program at Johns Hopkins University, and served on the faculty of Harvard Medical School and the Brigham & Women’s Hospital in Boston prior to joining the industry. Dr. Garg is a member of the Board of Directors of SQZ Biotechnologies (SQZ).

What is Pushkal Garg's net worth?

The estimated net worth of Pushkal Garg is at least $744,081.25 as of August 7th, 2023. Dr. Garg owns 4,345 shares of Alnylam Pharmaceuticals stock worth more than $744,081 as of December 11th. This net worth evaluation does not reflect any other assets that Dr. Garg may own. Additionally, Dr. Garg receives an annual salary of $1,000,000.00 as CMO at Alnylam Pharmaceuticals. Learn More about Pushkal Garg's net worth.

How old is Pushkal Garg?

Dr. Garg is currently 55 years old. There are 4 older executives and no younger executives at Alnylam Pharmaceuticals. The oldest executive at Alnylam Pharmaceuticals is Dr. Yvonne L. Greenstreet M.B.A., MBChB, CEO & Director, who is 60 years old. Learn More on Pushkal Garg's age.

What is Pushkal Garg's salary?

As the CMO of Alnylam Pharmaceuticals, Inc., Dr. Garg earns $1,000,000.00 per year. There are 2 executives that earn more than Dr. Garg. The highest earning executive at Alnylam Pharmaceuticals is Dr. Yvonne L. Greenstreet M.B.A., MBChB, CEO & Director, who commands a salary of $2,090,000.00 per year. Learn More on Pushkal Garg's salary.

How do I contact Pushkal Garg?

The corporate mailing address for Dr. Garg and other Alnylam Pharmaceuticals executives is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Alnylam Pharmaceuticals can also be reached via phone at (617) 551-8200 and via email at [email protected]. Learn More on Pushkal Garg's contact information.

Has Pushkal Garg been buying or selling shares of Alnylam Pharmaceuticals?

Pushkal Garg has not been actively trading shares of Alnylam Pharmaceuticals over the course of the past ninety days. Most recently, Pushkal Garg sold 4,166 shares of the business's stock in a transaction on Monday, August 7th. The shares were sold at an average price of $183.89, for a transaction totalling $766,085.74. Following the completion of the sale, the chief marketing officer now directly owns 4,345 shares of the company's stock, valued at $799,002.05. Learn More on Pushkal Garg's trading history.

Who are Alnylam Pharmaceuticals' active insiders?

Alnylam Pharmaceuticals' insider roster includes Jeffrey Dunn (CEO), Indrani Franchini (EVP), Pushkal Garg (CMO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Steven Paul (Director), Jeffrey Poulton (CFO), Phillip Sharp (Director), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Alnylam Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 12 times. They sold a total of 52,690 shares worth more than $10,316,756.20. The most recent insider tranaction occured on August, 7th when CMO Pushkal Garg sold 4,166 shares worth more than $766,085.74. Insiders at Alnylam Pharmaceuticals own 1.4% of the company. Learn More about insider trades at Alnylam Pharmaceuticals.

Information on this page was last updated on 8/7/2023.

Pushkal Garg Insider Trading History at Alnylam Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/7/2023Sell4,166$183.89$766,085.744,345View SEC Filing Icon  
8/4/2023Sell3,461$185.85$643,226.858,511View SEC Filing Icon  
4/27/2023Sell1,839$194.59$357,851.016,800View SEC Filing Icon  
3/3/2023Sell18,072$200.00$3,614,400.004,345View SEC Filing Icon  
See Full Table

Pushkal Garg Buying and Selling Activity at Alnylam Pharmaceuticals

This chart shows Pushkal Garg's buying and selling at Alnylam Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alnylam Pharmaceuticals Company Overview

Alnylam Pharmaceuticals logo
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $170.92
Low: $168.85
High: $173.00

50 Day Range

MA: $165.94
Low: $151.41
High: $178.96

2 Week Range

Now: $170.92
Low: $148.10
High: $242.97


539,518 shs

Average Volume

672,365 shs

Market Capitalization

$21.45 billion

P/E Ratio


Dividend Yield